-

Charles River Laboratories to Host Virtual Investor Day

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced that it will host a virtual Meeting with Management on Thursday, September 21st, beginning at 8:30 a.m. ET.

This virtual event will feature presentations from its senior management team, including an overview of the Company’s strategic focus, business developments, and updated financial targets, with a focus on the progress of its environmental, social, and governance (ESG) and digital initiatives.

The webcast of this virtual event may be accessed through a link that is posted on the Investor Relations section of the Company's website at ir.criver.com. The associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures will also be posted on the same website at approximately 8:00 a.m. ET on Thursday, September 21st. Following the event, a replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Contact:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com

Media Contact:
Amy Cianciaruso
Corporate Vice President,
Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories to Host Investor Day on September 21, 2023
Release Versions
$Cashtags

Contacts

Investor Contact:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com

Media Contact:
Amy Cianciaruso
Corporate Vice President,
Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Leverages Virtual Control Groups in GLP Studies

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen....

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new drugs...

Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r...
Back to Newsroom